Blog
Feedback
schliessen

Filtern

 

Bibliotheken

Logo der Bibliothek

Logo FID Pharmazie PubPharm Discovery System Universitätsbibliothek Braunschweig Institut für Informationssysteme

Use of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and Hospitalisation : = STerOids in COVID Study

At the time of writing (3/4/2020), close to a million people have been infected by the SARS-CoV-2 coronavirus around the world. The severe clinical condition that leads to deaths is now called CoVID-19. Currently, there are no effective treatments for the early or late stages of this illness. Governments worldwide have undertaken dramatic interventions to try and reduce the rate of spread of this deadly coronavirus. Early data from multiple studies in China, where the virus originated, show that severe cases of CoVID-19 are not as prevalent in patients with chronic lung diseases as expected. This data has been confirmed the Italian physicians. We think that the widespread use of inhaled corticosteroids reduces the risk of CoVID-19 pneumonia in patients with chronic lung disease. Early microbiological data also shows that these corticosteroids are effective at slowing down the rate of coronavirus replication on lung cells. Inhaled corticosteroids are widely used to manage common lung conditions, such as asthma. This type of medicine is among the top 3 most common medication prescribed around the world. Their safety is well understood, and their potential side effects are mild and reversible. We propose to test this idea that, in participants early in the course of CoVID-19 illness, daily high dose inhaled corticosteroids for 28 days, will reduce the chances of severe respiratory illness needing hospitalisation. We will also study the effect of this inhaled therapy on symptoms and viral load.

Year of Publication: 2020
Published: Bethesda (Maryland), ClinicalTrials.gov, June 4, 2020
Language: English
Full text access: Full text access (free access)
Links: Full Text (clinicaltrials.gov)
Keywords: Clinical Study Status: Not yet recruiting
Clinical Study
Clinical Trial, Phase II
Coronavirus Infection
Coronavirus Infections > MeSH
Forschungsbericht
Infection > MeSH
Klinische Studie
Severe Acute Respiratory Syndrome > MeSH
Notes: Source: ClinicalTrials.gov (no modifications made)
ClinicalTrials.gov processed this data on June 05, 2020
Last update posted on ClinicalTrials.gov: June 4, 2020
Last updated: 2020-06-08
NCT ID:
    NCT04416399

Associated Publications

  • Associated records are being queried...
more (+)
Internes Format
LEADER 03312nam a22005052 4500
001 CTG003413780
003 DE-627
005 20200609024511.0
007 cr uuu---uuuuu
008 200609s2020 xx |||||ot 00| ||eng c
028 5 2 |a CTg_2020-06-08.pp 
035 |a (DE-627)CTG003413780 
035 |a (DE-599)NCTNCT04416399 
035 |a (NCT)STOIC study 
035 |a (NCT)NCT04416399 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
084 |a PHARMAZIE  |q DE-84  |2 fid 
084 |a pha  |2 ssgn 
245 1 0 |a Use of High Dose Inhaled Corticosteroids as Treatment of Early COVID-19 Infection to Prevent Clinical Deterioration and Hospitalisation  |b  = STerOids in COVID Study 
246 3 1 |a STerOids in COVID Study 
264 1 |a Bethesda (Maryland)  |b ClinicalTrials.gov  |c June 4, 2020 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Source: ClinicalTrials.gov (no modifications made) 
500 |a ClinicalTrials.gov processed this data on June 05, 2020 
500 |a Last update posted on ClinicalTrials.gov: June 4, 2020 
500 |a Last updated: 2020-06-08 
520 |a At the time of writing (3/4/2020), close to a million people have been infected by the SARS-CoV-2 coronavirus around the world. The severe clinical condition that leads to deaths is now called CoVID-19. Currently, there are no effective treatments for the early or late stages of this illness. Governments worldwide have undertaken dramatic interventions to try and reduce the rate of spread of this deadly coronavirus. Early data from multiple studies in China, where the virus originated, show that severe cases of CoVID-19 are not as prevalent in patients with chronic lung diseases as expected. This data has been confirmed the Italian physicians. We think that the widespread use of inhaled corticosteroids reduces the risk of CoVID-19 pneumonia in patients with chronic lung disease. Early microbiological data also shows that these corticosteroids are effective at slowing down the rate of coronavirus replication on lung cells. Inhaled corticosteroids are widely used to manage common lung conditions, such as asthma. This type of medicine is among the top 3 most common medication prescribed around the world. Their safety is well understood, and their potential side effects are mild and reversible. We propose to test this idea that, in participants early in the course of CoVID-19 illness, daily high dose inhaled corticosteroids for 28 days, will reduce the chances of severe respiratory illness needing hospitalisation. We will also study the effect of this inhaled therapy on symptoms and viral load. 
650 4 |a Clinical Study Status: Not yet recruiting 
650 4 |a Coronavirus Infection 
650 4 |a Clinical Study 
650 4 |a Klinische Studie 
650 4 |a Clinical Trial, Phase II 
650 4 |a Infection  |x MeSH 
650 4 |a Coronavirus Infections  |x MeSH 
650 4 |a Severe Acute Respiratory Syndrome  |x MeSH 
655 7 |a Forschungsbericht  |2 gnd-content 
710 2 |a University of Oxford  |e Herausgebendes Organ  |4 isb 
856 4 0 |u https://clinicaltrials.gov/show/NCT04416399  |z Kostenfrei  |3 Volltext 
912 |a GBV_CTG 
936 u w |j 2020  |b 4  |c 06 
951 |a BO 
952 |j 2020  |b 4  |c 06